

**In the Claims**

Claim 1. (Currently amended) An allogeneic immunotherapeutic immunogenic agent comprising ~~three human prostate cell lines from three different sources, wherein cell lines are selected from the group consisting of:~~

- (a) normal prostate human PNT/2 ~~(ECCACC 95012613)~~,<sup>delete</sup>
- (b) primary prostate human NIH-1542 ~~(ATCC CRL-12037)~~,<sup>delete</sup> and
- (c) cancerous prostate human LNCap (ATCC CRL-1740).

Claims 2-10. (Canceled).

Claim 11. (Currently amended) An allogeneic immunogenic composition

comprising ~~the immunotherapeutic~~ (1) an allogeneic immunogenic agent

comprising three human prostate cell lines from three different sources, wherein cell lines are selected from the group consisting of:

- (a) normal prostate human PNT/2 (ECCACC 95012613),
- (b) primary prostate human NIH-1542 (ATCC CRL-12037), and
- (c) cancerous prostate human LNCap (ATCC CRL-1740)

~~of claim 1, combined with~~ and (2) a vaccine adjuvant selected from the group consisting of BCG, *M. Vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and non-specific adjuvants.

<sup>3</sup>  
Claim ~~12~~. (Currently amended) An immunogenic composition comprising the immunotherapeutic (1) an allogeneic immunogenic agent comprising ~~three human prostate cell lines from three different sources, wherein cell lines are selected from the group consisting of:~~

- delete delete*
- (a) normal prostate human PNT/2 (ECCACC 95012613),  
(b) primary prostate human NIH-1542 (ATCC CRL-12037), and  
(c) cancerous prostate human LNCap (ATCC CRL-1740)

of claim 1 and (2) a vaccine adjuvant, wherein the adjuvant is a mycobacterial preparation.

Claims 13-25. (Canceled).

<sup>4</sup>  
Claim ~~26~~. (Currently amended) The allogeneic ~~immunotherapeutic~~ immunogenic agent of claim 1, wherein the cell lines are rendered replication-incompetent by irradiation.